Summary of clinical trial data and efficacy and safety studies of Quizartinib

Quizartinib is an oral, second-generation FLT3 tyrosine kinase inhibitor mainly used to treat patients with acute myeloid leukemia (AML) carrying FLT3-ITD (internal tandem duplication) mutations. FLT3mutations are common driver mutations in AML and are often associated with poorer disease prognosis and higher risk of relapse. Quizartinib has a highly selective inhibitory effect on the FLT3-ITD mutation and can effectively block abnormal signaling, thereby inhibiting the proliferation and survival of leukemia cells. In recent years, with in-depth research on the clinical value of quizartinib, its potential in the treatment of AML has gradually emerged, and it has become an emerging targeted drug that has attracted much attention.

Clinical trial data show that quizartinib shows significant efficacy in the treatment of FLT3-ITD-positive relapsed or refractory AML patients. QuANTUM-R The Phase III clinical trial is one of the most representative studies of Quizartinib. This study randomly compared the efficacy and safety of Quizartinib with standard chemotherapy in patients with FLT3-ITD positive relapsed/refractory AML. The results showed that the overall survival time in the quizartinib group was significantly prolonged, with the median survival time reaching 6.2 months, while that in the control group was 4.7 months, showing an approximately 32% reduction in the risk of death. In addition, the complete response rate and partial response rate of patients in the quizartinib group were also higher than those in the control group, suggesting that the drug can significantly improve the treatment response rate.

In terms of safety, the side effects of quizartinib are relatively controllable, but there are also certain risks. The most common adverse reactions include gastrointestinal symptoms (such as nausea, vomiting, diarrhea), bone marrow suppression (manifested by neutropenia, anemia, and thrombocytopenia), and cardiac-related adverse events such as QT interval prolongation. EspeciallyQTInterval prolongation requires great attention because it may lead to severe arrhythmias and even sudden death. Therefore, during treatment with quizartinib, the patient's electrocardiogram and electrolyte levels need to be closely monitored, and the dosage should be adjusted or treatment suspended in a timely manner. Overall, the safety profile of quizartinib is within the acceptable range, but individualized management is required.

Quizatinib not only shows potential in relapsed and refractory AML, its application in first-line treatment is also being actively explored. For example, the QuANTUM-First trial was designed to evaluate the efficacy of quizartinib in combination with standard induction and consolidation chemotherapy in patients with newly diagnosed FLT3-ITDpositive AML. Preliminary data show that the response rate and progression-free survival of the combination treatment group are better than those of the chemotherapy alone group, suggesting that quizartinib is expected to become an important part of the standard treatment of AML patients in this subgroup. In addition, Quizartinib is also exploring its combination with other targeted drugs and immunotherapy in order to overcome resistance to single-agent therapy and improve the depth and durability of treatment.

In summary, quizartinib, as a targeted inhibitor targeting FLT3-ITD mutations, has shown positive clinical value in the treatment of AML. It significantly prolongs the survival time of patients with relapsed/refractory AML, improves the treatment response rate, and at the same time, the toxic and side effects are relatively controllable. In the future, as the results of more large-scale, multi-center clinical trials are announced, quizartinib is expected to expand its indications, optimize treatment options, and further improve the prognosis of AML patients. Clinicians should use quizartinib scientifically and rationally based on the patient's specific condition, genetic mutation status and tolerance to achieve precise treatment goals.

Reference materials:https://www.drugs.com/